Sandoz

The “Making Access Happen Consensus Statement”, co-created with patient advocates worldwide, outlines key strategies for making healthcare more accessible through generic and biosimilar medicines, from resilient supply chain to global collaboration. Read the full statement and join the community of #MakingAccessHappen: https://lnkd.in/dnmMuDr4 #AccessToMedicines #HealthEquity #Biosimilars #GenericMedicines #GlobalCollaboration

Antimicrobial resistance (AMR) is often mistakenly described as the ‘sleeping’, or ‘silent’ pandemic. Mistakenly, because it is anything but dormant – indeed, it is directly responsible for nearly 1.3 million deaths every year, more than malaria and HIV combined, and many of them in developed economies. How best to combat this growing global health threat – and the parallel threat of an increasingly dysfunctional market framework for antibiotics -- is the key theme of a panel discussion today (September 5) at the World AMR Congress in Philadelphia, sponsored by Sandoz, with the company represented by our Global AMR Program Lead, Dr. Boumediene Soufi. Find out more about the threat of AMR, how best to combat it, and the key role played by Sandoz as the world’s leading provider of generic antibiotics in driving responsible access to these critical medicines: https://lnkd.in/dEi4Ghsm #AMR

*Another #sustainability milestone for Sandoz* We are proud that our Kalwe manufacturing site in Navi Mumbai, India, is now being powered by renewable energy - the result of our first Power Purchase Agreement (PPA) as an independent company. Through this, we are demonstrating our commitment to sustainable, cost-effective energy solutions, and are setting new industry sustainability standards in India. A huge thank you to the teams who made it happen. #RenewableEnergy #Decarbonization

Long-term, deflated generic prices could render the market untenable for manufacturers, whose commitment is necessary to prevent the continued medicine shortages we see today. Sandoz is committed to identifying and promoting solutions that make a difference for patients and the US healthcare system in partnership with advocates and policymakers. Together, we can overcome the barriers impacting the availability of generics - like ensuring reliability in manufacturing - so that there is consistent access to high-quality medicines for all patients, and long-term sustainability of a competitive market for these much-needed medicines. What happens next must happen now. Learn more about what Sandoz is doing at www.us.sandoz.com #PioneeringAccess

🌟 Women leading change at Sandoz 🌟 Sandoz is leading the way in female representation among major Swiss companies, with 45% of our executives being women, according to an analysis prepared by news wire service AWP Finanznachrichten AG in May this year. And a story published just this week by Swiss national daily Tages-Anzeiger features five women on our executive team driving meaningful change throughout the company 👇 Our corporate culture supports work-life balance, ensuring career progression isn’t hindered by personal responsibilities. Keren Haruvi Snir, President of North America and member of the Sandoz executive team, notes, “I am one and the same person in my private and professional life, and I can stand by that.” Women at Sandoz lead with collaboration and purpose. Chief Scientific Officer Claire D'Abreu-Hayling emphasizes inclusive decision-making, while incoming Chief Commercial Officer Rebecca Guntern believes in keeping patients at the forefront of our work. Chief Legal Officer Ingrid Sollerer aligns her role with her personal values, advocating for affordable medicines. Last but not least, diversity at Sandoz extends beyond gender, incorporating various backgrounds and experiences to fuel innovation. As Chief People Officer Tripti Jha says, “It’s not just about more women, but about more diversity.” Read the full story in German on: https://lnkd.in/dGrW_xBJ Please note a subscription is required to access the full article. #Sandoz #WomenInLeadership #Diversity

Off-patent medicines are crucial in expanding patient access to affordable high-quality treatment options. An area of growing focus is complex generic medicines. However, they are typically difficult to develop and face complicated regulatory frameworks that differ across jurisdictions. The FDA and EMA parallel scientific advice (PSA) program for complex generic medicines aims to harmonize regulatory requirements across the US and EU, thereby reducing development costs and potentially decreasing time to market. With these obvious benefits, why has uptake of the program been so low since its launch in 2021? To help answer this question, our Global Head of Regulatory Affairs, Michael Banks recently shared his views with STAT. In this opinion piece, Michael explores the program’s systemic practical limitations. He also discusses the ways the off-patent industry and regulators could work together to optimize the program to help it deliver on its potential for expanding patient access in the future. Access Michael’s op-ed in full here: https://lnkd.in/dfKBPwuX #Sandoz #PatientAccess #GenericMedicines

Healthcare costs are increasing worldwide, so the availability of affordable medicines is essential. This can lead to improved clinical outcomes for millions of patients. That’s what inspires physician Shaloo Pandhi to work with Sandoz. Here, medical practitioners can make an impact on humanity at scale! Learn more: sandoz.com/careers #SandozLife #Sandoz #Careers

Today we announced the #Sandoz second-quarter net sales and half-year results. As I look back on this day of numerous interviews and calls, and reflect on the first half of the year as a whole, I feel we are making good progress on our journey as an independent company. In the second quarter, net sales were USD 2.6 billion, an increase of 9% in constant currencies compared to the same quarter in the prior year. For the half year, net sales were USD 5.0 billion, an increase of 7% in constant currencies over the prior year, and the core EBITDA margin was 17.5%. As I said in a live interview on CNBC with Karen Tso and Arabile Gumede this morning: We are continuing and building on the momentum we have seen on the top line and I am pleased that we have raised our full year net sales guidance. We now expect our top line to grow mid- to high-single digits in constant currencies and we have reaffirmed our confidence in our core EBITDA margin of around 20%. We are clearly executing on our strategy and I am particularly pleased with the progress of our biosimilars business. In recent months, we have seen strong uptake of Hyrimoz® (adalimumab) in the US, received approval for Pyzchiva® (ustekinumab) and Wyost®/Jubbonti® (denosumab) in the US and Europe, and secured a settlement agreement in the US with launch dates in the first half of 2025. This is great news for the patients we hope to serve with these important biotechnology medicines! I would like to thank our more than 20,000 Sandoz colleagues for all their contributions to making our spin-off the success it is proving to be. Thank you - you make a big difference in healthcare every day!

📊 Sandoz Reports Solid H1 and Q2 Results 📈 At Sandoz, we are delivering on our strategy and achieving significant milestones as we continue our journey as a standalone company. Our second-quarter and half-year 2024 results reflect the strength of our biosimilars business and the progress we're making in transforming our organization. Key highlights: ➡️ Double-digit growth in biosimilars, with sales up 29%, driven by the robust performance of our existing portfolio and recent launches. ➡️ Q2 net sales reached USD 2.6 billion, marking a 9% increase in constant currencies, supported by positive contributions across all regions. ➡️ H1 net sales totaled USD 5.0 billion, up 7% in constant currencies, showcasing the impact of our strategic focus on high-growth areas. ➡️ Core EBITDA margin improved to 17.5%, reflecting the benefits of our recent biosimilars launches and ongoing transformation efforts. ➡️ Growth guidance for 2024 has been raised to mid- to high-single digits, underscoring our confidence in achieving a core EBITDA margin of around 20%. We are also pleased to welcome Rebecca Guntern as Chief Commercial Officer and Christophe DELENTA as President Europe, effective September 1, 2024. Their leadership will be pivotal as we continue to build momentum in the second half of the year and beyond. These results and strategic achievements reinforce our commitment to pioneering access for patients and driving sustainable growth. Read the full release here: https://lnkd.in/ew3wskd3 #Sandoz #Generics #Biosimilars #Access #Growth

Recently, our Chief Scientific Officer Claire D'Abreu-Hayling joined a panel of women in pharma to discuss the impact of Brexit on drug development at Women of Color in Pharma (WOCIP)'s Global Conversations and Connections event earlier this week. 💊    Drawing on her own experiences of living and working in the UK, Claire shared her insights on the evolving landscape of drug development. The panel sparked some thought-provoking discussions on the positives and challenges the UK faces after leaving the EU.     Topics included:  ☑️ Regulation of off-patent medicines, which currently fill four out of five of all NHS prescriptions and deliver savings of around £16 billion per year to the NHS  🔬 The impact on diversity and science in the UK, where it’s evident that the world-class science and research capabilities remain       #Sandoz #DrugDevelopment #Brexit